

CURRICULUM VITAE

María del Carmen Clapp Jiménez L

clapp@unam.mx

<http://personal.inb.unam.mx/clapp/>

EDUCATION/TRAINING

B.S.: Biology. Metropolitan University (UAM), México, DF (1974-1978).

M.S.: Physiology, National University of Mexico (UNAM), México City (1980-1983).

Ph.D.: Physiology, National University of Mexico (UNAM), México City (1982-1984).

Post-doc: Physiology-Anatomy, University of California Berkeley, California, USA (1985-1988)

CURRENT POSITION (since 2002)

Professor, Institute of Neurobiology, UNAM, Querétaro, México; National System of Research Emeritus (Member since 1984)

HONORS: Biotechnology Career Fellowship. Rockefeller Foundation (1989-1995); Fellow "John Simon Guggenheim Memorial Foundation (1994); Research Award of the Mexican Academy of Science (1995); Young researcher award UNAM (1995); International Research Scholar of the Howard Hughes Medical Institute (1997-2002); José Santos Ophthalmology Award (2001 and 2007); GEN award for research on defects at birth (2005 and 2008); Medical Research Award "Dr. Jorge Rosenkranz" Grupo ROCHE-SYNTEX (2006); Biennial Research Award on Ophthalmology (2006); Research award by the Mexican Chamber of Pharmaceutical Laboratories (CANIFARMA) (2008). Research Award in Diabetic Retinopathy, Mexican Health Foundation (2011). Lifetime Scientific Achievements Award, Queretaro University (2013). UNAM Award in Natural Sciences 2016 (PUN 2016). Clinical Investigation Award 2017, Foundation Miguel Alemán Valdés. Award by the Program of Patent and Innovation (PROFOPI) 2020, UNAM. Mexican Women Scientist Award L'Oréal-UNESCO-AMC, 2021. Emeritus Scientist of the National System of Researchers (2022-). Pharmaceutical Innovation Award 2021, 6a. Edition from Mexican Pharmaceutical Council and Health Foundation. Ophthalmology Innovation Award FUNDSALUD 2023. Basic Research award by CANIFARMA (2024)

EDITORIAL BOARD: American Journal of Physiology: Regulatory, Integrative & Comparative Physiology (2008-); European Journal of Cell Biology (2010-), Frontiers in Vascular Physiology (2011-), Endocrinology (2020-), Frontiers in Endocrinology (2022-).

PATENT:

Granted: Mexico. *Title:* Oligopéptidos Inhibidores de la Angiogénesis y de la Función Vascular
Inventors: Carmen Clapp, Juan Pablo Robles, Magdalena Zamora, Gonzalo Martínez de la Escalera, Jakob Triebel, Thomas Bertsch. *Application No.* MX/E/2019/079075. *Filing Date:* November 20, 2019. *Publication No.* MX/E/2019/079075. *Publication Date:* May 2021 (Gaceta de la Propiedad Industrial, México)

Filed Patent Applications: *International-PCT* (Patent Cooperation Treaty). *Title:* Oligopeptides that inhibits angiogenesis and vascular function. *Inventors:* Carmen Clapp, Juan Pablo Robles, Magdalena Zamora, Gonzalo Martínez de la Escalera, Jakob Triebel, Thomas Bertsch. *PCT Application No.:* PCT/EP2020/069154. *Filing Date:* July 7, 2020. *Publication No.:* WO2021098996. *Publication Date:* May 27, 2021. <https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021098996>

National Phase Entries: USA (US17/778,396; Exp. P2022/13828US), Japan (Exp. P2022/13827JP), China (Exp. P2022/13825CN), and Europe (EP20740261.1; Exp 109205320).

SCIENTIFIC SOCIETIES (8)

THESIS: B.S. (14), M.S. (33), Ph.D. (31)

SYMPOSIA (85)

ABSTRACTS (358)

PUBLICATIONS Articles: 166 (average impact: 4.6); Book chapters: 20; Citations: 6975 (June 2025)

ARTICLES (71 in last 10 years; 44 in the last 3 years):

168. García-González MA, Miguel-Martínez AD, González-Hernández A, Zamora M, Adán-Castro E, Triebel J, Bertsch T, López-López JG, Martínez de la Escalera G, Robles JP, Clapp C, Villalón CM. (2025). Cardiovascular safety of VIAN-c4551, an antiangiogenic peptide derived from vasoinhibin. *Drug Development Research*, Under revision, 2025. FI: 3.500
167. Adán-Castro E, Zamora M, Granados-Carrasco D, Siqueiros-Marquez L, García-Rodrigo JF, Bertsch T, Triebel J, Martínez de la Escalera G, Robles JP, Clapp C. Topical eye administration of the antiangiogenic peptide VIAN-c4551 for the treatment of diabetic macular edema: efficacy and ocular pharmacokinetics. *Scientific Reports*, Under revision, 2025. FI: 3.800
166. Pérez AL, Zamora M, Bahena M, Arámburo-Williams R, Adán-Castro E, Bertsch T, Triebel J, Martínez de la Escalera G, Robles JP, Clapp C. The antiangiogenic peptide VIAN-c4551 inhibits lung melanoma metastasis in mice by reducing pulmonary vascular permeability. *PLOS ONE*, 20(5): e0316983, 2025. <https://doi.org/10.1371/journal.pone.0316983>. FI: 3.752
165. Nuñez FF, Siqueiros-Marquez L, Adán-Castro E, Zamora M, Robles JP, Ruíz-Herrera X, Bertsch T, Triebel J, Martínez de la Escalera G, Clapp C. Vasoinhibin is generated by the renin-angiotensin system. *Endocrinology* 166, bqaf023, 2025. <https://doi.org/10.1210/endocr/bqaf023>. FI: 5.054
164. Macías F, Ulloa M, Clapp C, Martínez de la Escalera G, Arnold E. Prolactin protects hippocampal neurons against H₂O₂-induced neurotoxicity by suppressing BAX and NOX4 via the NF-κB signaling pathway. *PLOS ONE*, 19:e0313328, 2024. <https://doi.org/10.1371/journal.pone.0313328>. FI: 3.752
163. Zamora M, Harris D, Davies N, Ebnet J, Radermacher P, Brucker C, Waller C, Robles JP, Bertsch T, Clapp C, Triebel J. Immunometric and functional measurement of endogenous vasoinhibin in human sera. *Frontiers in Endocrinology* 15:1345996, 2024. <https://doi.org/10.3389/fendo.2024.1345996>. FI: 6.055
162. Castillo X, Ortíz G, Arnold E, Wu Z, Tovar y Romo LB, Clapp C, Martínez de la Escalera G. The influence of the prolactin/vasoinhibin axis on post-stroke lesion volume, astrogliosis, and survival. *Journal of Neuroendocrinology* 2024:e13415. <https://doi.org/10.1111/jne.13415>. FI: 3.200
161. Ulloa M, Macías F, Clapp C, Martínez de la Escalera G, Arnold E. Prolactin is an endogenous antioxidant factor in astrocytes that limits oxidative stress-induced astrocytic cell death via the STAT3/NRF2 signaling pathway. *Neurochemical Research* 49: 1879-1901, 2024. <https://doi.org/10.1007/s11064-024-04147-3>. FI: 4.400
160. Vázquez-Carrillo DI, Ocampo-Ruiz AL, Báez-Mesa A, Ramírez-Hernández G, Adán-Castro E, García-Rodrigo JF, Dena-Beltrán JL, de los Ríos EA, Sánchez-Martínez MK, Ortíz-Arballo MG, Martínez de la Escalera G, Clapp C, Macotela Y. Dopamine D2 receptor antagonist counteracts hyperglycemia and insulin resistance in diet-induced obese male mice. *PLOS ONE* 19:e0301496, 2024. <https://doi.org/10.1371/journal.pone.0301496>. FI: 3.752
159. Robles JP, Zamora M, García-Rodrigo JF, Perez AL, Bertsch T, Martínez de la Escalera G, Triebel J, Clapp C. The apoptotic, inflammatory, and fibrinolytic actions of vasoinhibin are in a motif different from its antiangiogenic HGR motif. *Endocrinology* 165:1-12, 2024. <https://doi.org/10.1210/endocr/bqad185>. FI: 5.045
158. Núñez-Amaro CD, López M, Adán-Castro E, Robles-Osorio ML, García-Franco L, García-Roa M, Villalpando-Robles Y, Ramírez-Neria P, Pineiro N, Rubio-Mijangos JF, Sánchez J, Ramírez-Hernández G, Siqueiros-Márquez L, Díaz-Lezama N, López-Star E, Bertsch T, Martínez de la Escalera G, Triebel J, Clapp C. Levosulpiride for the treatment of diabetic macular oedema: A phase 2 randomized clinical trial. *EYE* 38:520-528, 2024. <http://doi.org/10.1038/s41433-023-02715-5>. FI: 4.456

157. Luzardo-Ocampo I, Ocampo-Ruiz AL, Dena-Beltrán JL, Martínez de la Escalera G, Clapp C, Macotela Y. The diversity of gut microbiota at weaning is altered in prolactin receptor null mice. *Nutrients* 15:3447, 2023. <http://doi.org/10.3390/nu15153447>. FI: 5.717
156. García-Rodrigo JF, Ortíz-Arballo G, Martínez-Díaz OF, Furuzawa-Carballeda J, Ruiz-Herrera X, Macías F, Ledesma-Colunga MG, Martínez de la Escalera G, Clapp C. Prolactin inhibits or stimulates the inflammatory response of joint tissues in a cytokine-dependent manner. *Endocrinology* 1-14, bqad156, 2023. <https://doi.org/10.1210/endocr/bqad156>. FI: 5.045
155. Ruiz-Herrera X, Luzardo-Ocampo I, Martínez de la Escalera G, Clapp C, Macotela Y. Differentiated mouse adipocytes in primary culture: A model of insulin resistance. *Journal of Visualized Experiments*. 192: E63979, 2023. <http://doi:10.3791/63979v>. FI: 1.424
154. Luzardo-Ocampo I, Dena-Beltrán JL, Martínez de la Escalera G, Clapp C, Macotela Y. Obesity-derived alterations in the lactating mammary gland: focus on prolactin. *Molecular and Celular Endocrinology* 559:111810, 2023. FI: 4.102
153. Macotela Y, Ruiz-Herrera X, Vázquez-Carrillo DI, Ramírez-Hernández G, Martínez de la Escalera G, Clapp C. The beneficial metabolic actions of prolactin. *Frontiers in Endocrinology* 13:1001703, 2022. FI: 6.055
152. Triebel J, Bertsch T, Clapp C. Prolactin and vasoinhibin are endogenous players in diabetic retinopathy revisited. *Frontiers in Endocrinology* 13:994898, 2022. FI: 6.055
151. Clapp C, Ortiz G, García-Rodrigo JF, Ledesma-Colunga MG, Martínez-Díaz F, Adán N, Martínez de la Escalera G. Dual roles of prolactin and vasoinhibin in inflammatory arthritis. *Frontiers in Endocrinology* 13:905756, 2022. Doi: 10.3389/fendo.2022.905756. FI: 6.055
150. Triebel J, Robles JP, Zamora Z, Clapp C, Bertsch. New horizons in specific hormone proteolysis. *Trends in Endocrinology and Metabolism* 33:371-377, 2022. FI: 12.015
149. Ortiz G, Ledesma-Colunga MG, Zhijian Wu Z, García-Rodrigo JF, Adán N, Martínez-Díaz F, de Los Ríos EA, López-Barrera F, Martínez de la Escalera G, Clapp C. Vasoinhibin is generated and promotes inflammation in mild antigen-induced arthritis. *Endocrinology* 163(5):1-12 2022. FI: 5.045
148. Martínez de la Escalera G, Macotela Y, Clapp C. A new experimental tool towards understanding the regulation of human prolactin secretion and functions. *Endocrinology* 163(4):1-2, 2022. FI: 5.045
147. Robles JP, Zamora M, Martínez de la Escalera G, Clapp C. The spike protein of SARS-CoV-2 induces endothelial inflammation through integrin α5β1 and NF-κB signaling. *Journal of Biological Chemistry* 298(3):101695, 2022. FI: 4.238
146. Leuchs A, Davies N, Friedrich C, Trier S, Clapp C, Bertsch T, Triebel J. A comparative phylogenetic analysis of prolactin cleavage sites for the generation of vasoinhibin in vertebrates. *General and Comparative Endocrinology* 320:114011, 2022. FI: 2.88
145. Markl-Hahn H, Neugebauer L, Lenke L, Ecker S, Merz T, McCook O, Khouder n, Bruckeer C, Radermacher P, Waller C, Clapp C, Bertsch T, Triebel J. Human placental tissue contains a placental lactogen derived vasoinhibin. *Journal of the Endocrine Society* 6:1-14, 2022. FI: 3.49
144. Hernández-Soto R, Adán-Castro E, Clapp C, Peña-Ortega F. Main olfactory bulb reconfiguration by prolonged passive olfactory experience correlates with increased brain-derived neurotrophic factor and improved innate olfaction. *European Journal of Neuroscience* 55:1141-1161, 2022. FI: 3.386
143. Adán-Castro E, Siqueiros-Márquez L, Ramírez-Hernández G, Díaz-Lezama N, Ruiz-Herrera X, Nuñez FF, Nuñez-Amaro CD, Robles-Osorio ML, Bertsch T, Triebel J, Martínez de la Escalera G, Clapp C. Sulpiride-induced hyperprolactinemia increases retinal vasoinhibin and protects against diabetic retinopathy in rats. *Journal of Neuroendocrinology: Translational and Clinical Neuroendocrinology* 34:e13091, 2022. doi:[10.1111/jne.13091](https://doi.org/10.1111/jne.13091). FI: 3.627

142. Robles JP, Zamora M, Siqueiros-Marquez L, Adan-Castro E, Ramirez-Hernandez G, Nuñez FF, Lopez-Casillas F, Millar RP, Bertsch T, Martínez de la Escalera G, Tiebel J, Clapp C. The HGR motif is the antiangiogenic determinant of vasoinhibin: implications for a therapeutic orally active oligopeptide. *Angiogenesis* 25:57-70, 2022. Doi: 10.1007/s10456-021-09800-x. FI: 9.78
141. Ruggiero C, Altieri B, Arnold E, Siqueiros-Marquez L, Doghman-Bouguerra M, Detomas M, Durand N, Jarjat M, Chatonnet F, Fassnacht M, Deutschbein T, Clapp C, Lalli E. Integrative genomic analysis reveals a conserved role for prolactin signalling in the regulation of adrenal function. *Clinical and Translational Medicine* 11: e630, 2021. Doi: <https://doi.org/10.1002/ctm2.630>, FI: 11.492
140. Friedrich C, Neugebauer L, Zamora M, Robles JP, Martínez de la Escalera G, Clapp C, Bertsch T, Tiebel J. Plasmin generates vasoinhibin-like peptides by cleaving prolactin and placental lactogen. *Molecular and Cellular Endocrinology*, 538:111471, 2021. FI: 4.102
139. Zamora M, Robles JP, Aguilar MB, Romero-Gómez SJ, Bertsch T, Martínez de la Escalera G, Tiebel J, Clapp C. Thrombin cleaves prolactin into a potent 5.6 kDa vasoinhibin: Implication for tissue repair. *Endocrinology* 162: 2021. Doi:10.1210/endocr/bqab177. FI: 5.045
138. Müller N, Robles JP, Zamora M, Ebnet J, Markl-Hahn H, Martínez de la Escalera G, Clapp C, Bertsch, Tiebel J. Development of vasoinhibin-specific monoclonal antibodies. *Frontiers in Endocrinology* 12:645085, 2021. DOI: 10.3389/fendo.2021.645085. FI: 3.675
137. Ramírez-Hernández G., Adán-Castro E., Díaz-Lezama N., Ruiz-Herrera X, Martínez de la Escalera G., Macotela Y, Clapp C. Global deletion of the prolactin receptor aggravates streptozotocin-induced diabetes in mice. *Frontiers in Endocrinology* 12:619696, 2021. DOI: 10.3389/fendo.2021.619696. FI: 3.675
136. Nuñez-Amaro C.D., Moreno-Vega A.I., Adan-Castro E., Zamora M., García Franco R., Ramirez-Neria P., Garcia-Roa M., Villalpando Y, Robles J.P., Ramirez-Hernandez G., Lopez M., Sanchez J., Lopez-Star E., Bertsch T., Martínez de la Escalera G., Robles-Osorio M.L., Tiebel J., Clapp C. Levosulpiride increases the levels of prolactin and antiangiogenic vasoinhibin in the vitreow of patients with proliferative diabetic retinopathy. *Translational Vision Science & Technology (TVST)* 9:27, 2020.
135. Ortiz G, Ledesma-Colunga M.G., Wu Z., Garcia-Rodrigo JF, Adan N, Martínez de la Escalera G, Clapp C. Vasoinhibin reduces joint inflammation, bone loss, and the angiogenesis and vasopermeability of the pannus in murine antigen-induced arthritis. *Laboratory Investigation* 100:1068-1079, 2020.
134. Macotela Y, Tiebel J, Clapp C. Time for a new perspective on prolactin in metabolism. *Trends in Endocrinology and Metabolism* 31:276-286, 2020. FI: 11.64
133. Vazquez-Membrillo M, Sigueiros-Marquez L, Nuñez FF, Diaz-Lezama N, Adan-Castro E, Ramirez-Hernandez G, Adán N, Macotela Y, Martinez de la Escalera G, Clapp C. Prolactin stimulates the vascularization of the retina in newborn mice under hyperoxia conditions. *J. Neuroendocrinology*, e12858, 2020. <https://doi.org/10.1111/jne.12858>
132. Ponce AJ, Galván-Salas T, Lerma-Alvarado RM, Ruiz-Herrera X, Cardenas LE, Hernandez T, Valencia R, Martínez de la Escalera G, Clapp C, Macotela Y. Low prolactin levels associate with visceral adipocyte hypertrophy and insulin resistance in humans. *Endocrine* 67:331-343, 2020. FI:3.878
131. Tiebel J, Schauer N, Zamora M, Moreno-Vega AI, Martínez de la Escalera G, Clapp C, Bertsch T. Matrix Metalloproteases and cathepsin D in human serum do not cleave prolactin to generate vasoinhibin. *Clinical Laboratory*. 66:877-866, 2020
130. Aroña RM, Arnold E, Macías F, López-Casillas F, Clapp C, Martínez de la Escalera G. Vasoinhibin generation and effect on neuronal apoptosis in the hippocampus of late mouse embryos.

- American J Physiol: Regulatory, Integrative, Comparative Physiology 318:R760-R771, 2020. FI: 3.529
129. Lemke L, Martínez de la Escalera G, Clapp C, Bertsch T, Triebel J. A dysregulation of the prolactin/vasoinhibin axis can contribute to preeclampsia. *Front Endocrinol (Lausanne)* 10:893, 2020
 128. Arnold, E., Thébault, S., Aroña, R.M., Martínez de la Escalera, G., Clapp, C. Prolactin mitigates deficiencies of retinal function associated with aging. *Neurobiology of Aging* 85: 38-48, 2019. FI: 5.153
 127. Pérez-Ortíz, A.C., Peralta-Ilddefonso, M.J., lira-Romero, E., Moya-Albor, E., Brieva, J., Ramírez-Zanchez, I., Clapp, C., Luna-Angulo, A., Rendón, A., Adan-Castro, E., Ramírez-Hernández, G., Díaz-Lezama, N., Coral-Vázquez, R.M., Estrada-Mena, F.J. Lack of delta-sarcoglycan (Sgcd) results in retinal degeneration resembling geographic atrophy AMD. *International Journal of Molecular Sciences* 20: 5480-, 2019. <https://doi:10.3390/ijms20215480>
 126. Moreno-Carranza, B., Robles, J.P., Cruces-Solís, H., Ferrer-Ríos, M.G., Aguilar-Rivera, E., Yupanki, M., Martínez de la Escalera, G., Clapp, C. Sequence optimization and glycosylation of vasoinhibin: Pitfalls of recombinant production. *Protein Expression and Purification* 161: 49-56, 2019. FI: 1.338
 125. Clapp, C., Díaz-Lezama, N., Adan-Castro, E., Ramírez-Hernandez, G., Moreno-Carranza, B., Sarti, A.C., Falzoni, S., Solini, A., Di Virgilio, F. Pharmacological blockade of the P2X7 receptor reverses retinal damage in a rat model of type 1 diabetes. *Acta Diabetologica Acta Diabetologica* 56:1031-1036, 2019. FI: 6.206
 124. Triebel, J., Robles, J.P., Zamora, M., Martínez de la Escalera, G., Bertsch, T, Clapp, C. Regulator of angiogenesis and vascular function: A 2019 update of the vasoinhibin nomenclature. *Frontiers in Endocrinology* 10: 214, 2019. DOI: 10.3389/fendo.2019.00214. FI: 3.675
 123. Melo, Z., Castillo, X., Moreno-Carranza, B., Ledesma-Colunga, M.G., López-Casillas, F., Ruíz-Herrera, X., Clapp, C., Martínez de la Escalera, G. Vasoinhibin suppresses nerve growth factor-induced differentiation and survival of PC12 pheochromocytoma cells. *Neuroendocrinology* 109:152-164, 2019. Doi: 10.1159/000499507. FI: 5.024
 122. Robles, J.P., Zamora, M., Velasco-Bolom, J.L., Tovar, M., Garduño-Juárez, R., Bertsch, T., Martínez de la Escalera, G., Triebel, J., Clapp, C. Vasoinhibins comprise a three-helix bundle and their antiangiogenic domain is located within the first 79 residues. *Scientific Reports* 8(17111):1-17, 2018. DOI: DOI:10.1038/s41598-018-35383-7. FI: 5.525
 121. Moreno-Carranza, B., Bravo-Manríquez, M., Baez, A., Ledesma-Colunga, M.G., Ruíz-Herrera, X., Reyes-Ortega, P., de los Ríos, E.A., Macotela, Y., Martínez de la Escalera, G., Clapp, C. Prolactin regulates liver growth during postnatal development in mice. *American Journal of Physiology: Regulatory, Integrative and Comparative Physiology* 314: R902-R908, 2018. DOI: 10.1152/ajpregu.00003.2018. FI: 3.529
 120. Robles-Osorio, L., García-Franco, R., Núñez-Amaro, D., Mira-Lorenzo, X., Ramírez-Neria, P., Hernández, W., López-Star, E., Bertsch, T., Martínez de la Escalera, G., Triebel, J., Clapp, C. Basis and design of a randomized clinical trial to evaluate the effect of levosulpiride on retinal alterations in patients with diabetic retinopathy and diabetic macular edema. *Frontiers in Endocrinology* 9: 242, 2018. DOI 10.3389/fendo.2018.00242. FI: 3.675
 119. de los Ríos, E.A., Ruíz-Herrera, X., Tinoco-Pantoja, V., López-Barrera, F., Martínez de la Escalera, G., Clapp, C., Macotela, Y. The effect of maternal high fat feeding during lactation on offspring metabolism involves altered PRL action on the mammary gland and reduced milk PRL levels. *FASEB J* 32: 3457-2470, 2018. DOI: 10.1096/fj.201701154R. FI: 5.595
 118. Castillo, X., Melo, Z., Varela-Echevarría, A., Tamáriz, E., Aroña, R.M., Arnold, E., Clapp, C., Martínez de la Escalera, G. Vasoinhibins suppresses the ability of NGF and VEGF to stimulate

- neurite growth in rat primary sensory neurons. *Neuroendocrinology* 106: 221-233, 2018. DOI:10.1159/000477768. FI: 5.024
117. Triebel, J., Robles-Osorio, M.L., Garcia-Franco, R., Martínez de la Escalera, G., **Clapp, C.**, Bertsch, T. From bench to bedside: translating the prolactin/vasoinhibin axis. *Frontiers in Endocrinology*, doi:10.3389/fendo.2017.00342. FI: 3.675
116. Zepeda-Romero, L.C., Vázquez-Membrillo, M., Adán-Castro, E., Gómez-Aguayo, F., Gutiérrez-Padilla, J.A., Angulo-Castellanos, E., Barrera de León, J.C., González-Bernal, C., Quezada-Chalita, A., Meza-Anguiano, A., Díaz-Lezama, N., Martínez de la Escalera, G., Triebel, J., **Clapp, C.** Higher prolactin and vasoinhibin serum levels associate with incidence and progression of retinopathy of prematurity. *Pediatric Research*, 81:473-479. FI: 2.76.
115. Triebel, J., **Clapp, C.**, Martínez de la Escalera, G., Bertsch, T. Remarks on the prolactin hypothesis of peripartum cardiomyopathy. *Frontiers in Endocrinology*, 8: 77, 2017. FI: 3.675
114. Ledesma-Colunga, M.G., Adán N., Ortiz, G., Solis-Gutierrez, M., López-Barrera, F., Martínez de la Escalera, G., **Clapp, C.** Prolactin blocks the expression of receptor activator of nuclear factor kB ligand and reduces osteoclastogenesis and bone loss in murine inflammatory arthritis. *Arthritis Research & Therapy* 19: 93-109, 2017. FI: 3.9
113. Triebel, J., **Clapp, C.**, Martínez de la Escalera, G., Bertsch, T. Commentary: Prolactin alters blood pressure by modulating the activity of endothelial nitric oxide synthase. *Frontiers in Endocrinology* 8: 105, 2017. FI: 3.675
112. Arredondo-Zamarripa, D., Noguez-Imm, R., Bautista Cortés, A.M., Vázquez-Ruiz, O., Bernanrdini, M., Fiorio Pla, A., Gkika, D., Prevarskaya, N., Prevarskaya, N., López-Casillas, F., Liedtke, W., **Clapp, C.**, Thebault, S. Dual contribution of TRPV4 antagonism in the regulatory effect of vasoinhibins on blood-retinal barrier permeability: diabetic milieus makes a difference. *Scientific Reports* 7: 13094-13109, 2017. FI: 5.525
111. Triebel, J., Martínez de la Escalera, G., **Clapp, C.**, Bertsch, T. Vasoinhibins may contribute to postpartum depression. *Frontiers in Psychiatry*, doi:10.3389/fpsyg.2007.00167, 2017. FI: 3.532.
110. Castillo, X., Melo, Z., Varela-Echevarría, A., Tamáriz, E., Aroña, R.M., Arnold, E., **Clapp, C.**, Martínez de la Escalera, G. Vasoinhibins suppresses the ability of NGF and VEGF to stimulate neurite growth in rat primary sensory neurons. *Neuroendocrinology* 2017. DOI:10.1159/000477768. FI: 4.373.
109. Triebel, J., **Clapp, C.**, Martínez de la Escalera, G., Bertsch, T. Vasoinhibin serum levels are required to demonstrate their role in peripartum cardiomyopathy etiopathology. *ASAIO Journal* 63: e50, 2017. FI: 2.291
108. Triebel, J., **Clapp, C.**, Martínez de la Escalera, G., Bertsch, T. Commentary: Prolactin alters blood pressure by modulating the activity of endothelial nitric oxide synthase. *Frontiers in Endocrinology* 8: 105, 2017. FI: 3.675
107. Ruiz-Herrera, X., de los Ríos, E.A., Díaz, M.M., Lerma-Alvarado, R.M., Martínez de la Escalera, L., López-Barrera, F., Lemini, M., Arnold, E., Martínez de la Escalera, G., **Clapp, C.**, Macotela, Y. Prolactin promotes adipose tissue fitness and insulin sensitivity in obese males. *Endocrinology*, accepted 2016. FI: 5.045
106. **Clapp, C.**, Adán, N., Ledesma-Colunga, G.M., Solís-Gutiérrez, M., Triebel, J., Martínez de la Escalera, G. The role of the prolactin/vasoinhibin axis in rheumatoid arthritis: An integrative overview. *Cellular and Molecular Life Sciences*. 73:2929-2948, 2016. FI: 5.808. DOI 10.1007/s00018-016-2187-0.
105. Meléndez García, R., Arredondo Zamarripa, D., Arnold, E., Ruiz-Herrera, X., Noguez Imm, R., Baeza Cruz, G., Adán, N., Binart, N., Riesgo-Escovar, J., Goffin, V., Ordaz, B., Peña-Ortega, F., Martínez-Torres, A., **Clapp, C.**, and Thebault, S.. Prolactin protects retinal pigment epithelium by inhibiting SIRT2-dependent cell death. *EBioMedicine* 7:35-49, 2016.
104. Díaz-Lezama, N., Wu, Z., Adán-Castro, E., Arnold, E., Vázquez-Membrillo, M., Arredondo-Zamarripa, D., Ledesma-Colunga, M.G., Moreno-Carranza, B., Martínez de la Escalera, G., Colosi, P., **Clapp, C.** Diabetes enhances the efficacy of AAV2 vectors in the retina: therapeutic effect of AAV2 encoding vasoinhibin and soluble VEGF receptor 1. *Laboratory Investigation* 96: 283-295, 2016. FI: 4.453
103. Triebel, J., Bertsch, T., Bollheimer, C., Ríos-Barrera, D., Pearce, C.F., Hüfner, M., Martinez de la Escalera, G., **Clapp, C.** Principles of the prolactin/vasoinhibin axis. *American Journal of*

- Physiology: Regulatory, Integrative and Comparative Physiology. 309: R1193-R1203, 2015. FI: 3.529
102. Lemini ,M., Ruiz-Herrera , X., Ledesma-Colunga, M.G., Díaz-Lezama, N., De los Ríos, E.A., Lopez-Barrera, F., Méndez, I., Martínez de la Escalera, G., Macotela, Y., and **Clapp C.** Prolactin anterior pituitary expression and circulating levels are reduced in obese and diabetic rats: Role of TGF β and TNF α . *American Journal of Physiology- Regulatory, Integrative and Comparative Physiology.* 308:R792-R799, 2015. FI: 3.59
 101. Triebel, J., Bertsch, T., Martínez de la Escalera, G., and **Clapp, C.** On the path towards classifying hormones of the vasoinhibin-family. *Frontiers in Endocrinology* 6:1-2, 2015
 100. Triebel, J., Moreno-Vega, A.I., Vázquez-Membrillo, M., Jeziorski, M.C., García-Franco, R., López-Star, E., Baldivieso-Hurtado, O., Ochoa, D., Macotela, Y., Bertsch, T., Martínez de la Escalera, G., **Clapp, C.** High prolactin excretion in patients with diabetes mellitus and impaired renal function. *Clinical Laboratory*, 61:709-716, 2015. FI:1.084
 99. **Clapp, C.**, Thebault, S., Macotela, Y., Moreno-Carranza, B., Triebel, J., Martínez de la Escalera, G. Regulation of blood vessels by prolactin and vasoinhibins. *Advances in Experimental Medicine and Biology* 846: 83-95, 2015. FI: 2.020.
 98. Arredondo, D., Díaz-Lezama, N., Meléndez, R., Chávez Balderas, J., Adán, N., Ledesma-Colunga, M.G., Arnold, E., **Clapp, C.**, Thebault, S. Vasoinhibins regulate the inner and outer blood-retinal barrier and limit retinal oxidative stress. *Frontiers in Cellular Neuroscience*. Doi: 10.3389/fncel.2014.00333. FI: 4.5
 97. Zamorano, M., Ledesma-Colunga, M.G., Adán, A., Vera-Massieu, C., Lemini, M., Méndez, I., Moreno-Carranza, B., Neumann I.D., Thebault, S., Martínez de la Escalera, G., Torner, L., **Clapp, C.** Prolactin-derived vasoinhibins increase anxiety- and depression-related behaviors. *Psychoneuroendocrinology*. 44: 123-132, 2014. FI: 5.926
 96. Adán, N., Ledesma-Colunga, M.G., Reyes-López, A.L., Martínez de la Escalera, G., **Clapp, C.** Arthritis and prolactin: A phylogenetic viewpoint. *General and Comparative Endocrinology*. Doi: 10.1016/j.ygcen.2014.01.011. FI: 3.108
 95. García, C., Nuñez-Arita, R.E., Thebault, S., Arredondo-Zamarripa, D., Jeziorski, M.C., Martínez de la Escalera, G., **Clapp, C.** Requirement of phosphorylatable endothelial nitric oxide synthase at Ser-1177 for vasoinhibin-mediated antiangiogenic effects. *Endocrine* 45(2): 263-270, 2014. FI: 2.250
 94. Arnold, E., Thebault, S., Baeza-Cruz, G., Arredondo Zamarripa, D., Adán, N., Quintanar-Stéphano, A., Condés-Lara, M., Rojas-Piloni, G., Binart, N., Martínez de la Escalera, G., **Clapp, C.** The hormone prolactin is a novel, endogenous trophic factor able to regulate reactive glía and to limit retinal degeneration. *Journal of Neuroscience* 34(5): 1868-1878, 2014. FI: 7.87.
 93. Lajud, N., Gonzalez-Zapien, R., Roque, A., Tinajero, E., Valdez, J.J., **Clapp, C.**, Torner L. Prolactin administration during early postnatal life decreases hippocampal and olfactory bulb neurogenesis and results in depressive-like behavior in adulthood. *Hormones and Behavior*, 64: 781-789, 2013. FI: 3.735
 92. Moreno-Carranza, B., Goya-Arce, M., Vega, C., Adán, N., Triebel, J., Lopez-Barrera, F., Quintanar-Stephano, A., Binart, N., Martínez de la Escalera, G., **Clapp, C.** Prolactin promotes normal liver growth, survival, and regeneration in rodents: effects on hepatic IL-6, suppressor of cytokine signaling-3, and angiogenesis. *American Journal of Physiology: Regulatory, Integrative and Comparative Physiology* 305: R720-R726, 2013. FI: 3.058
 91. Adán, N., Guzmán-Morales, J., Ledesma-Colunga, G., Perales-Canales, S.I., Quintanar-Stephano, A., López-Barrera, F., Méndez, I., Moreno-Carranza, B., Triebel, J., Binart, N., Martínez de la Escalera, G., Thebault, S., **Clapp, C.** Prolactin promotes cartilage survival and attenuates inflammation in rheumatoid arthritis. *Journal of Clinical Investigation* 123(9): 3902-3913, 2013. FI: 16.559